The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows improvements for patients with progressive liver disease, finds a clinical trial from China published on June 4 by The BMJ.
The results show that treatment with dapagliflozin improved metabolic dysfunction-associated steatohepatitis (MASH) — a condition where excess fat accumulates in the liver, leading to inflammation — and liver fibrosis (a build up of scar tissue)…
Continue Reading
News Source: www.sciencedaily.com
Leave a Reply